{"filing":{"accession_number":"0001193125-26-286957","cik":"0001858848","ticker":"TNYA","company_name":"Tenaya Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"tnya-20260629.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1858848/000119312526286957/tnya-20260629.htm"},"events":[{"id":14513,"run_id":12925,"accession_number":"0001193125-26-286957","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Eric Hyllengren was appointed as Chief Financial Officer effective July 13, 2026, with responsibility for Principal Financial Officer and Principal Accounting Officer roles. The appointment includes compensatory arrangements consisting of a base salary of $490,000, a 40% target bonus, and an option grant of 1,650,000 shares.","company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":11977,"accession_number":"0001193125-26-286957","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Eric Hyllengren as Chief Financial Officer effective July 13, 2026, with responsibility for Principal Financial Officer and Principal Accounting Officer roles. While the disclosure includes compensatory arrangements (base salary of $490,000, 40% target bonus, and 1,650,000 option grant), the principal disclosed action is the appointment of a named executive to a C-suite officer position. The filing also notes the transition of interim duties from Faraz Ali and Tomohiro Higa, but the core event is Hyllengren's appointment as CFO.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T13:01:55.620129+00:00","company_name":"","ticker":null,"filing_date":""},{"id":11978,"accession_number":"0001193125-26-286957","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing announces the appointment of Eric Hyllengren as Chief Financial Officer, effective July 13, 2026. While the press release also mentions the retirement of Hiro Higa, the principal disclosed action centers on the appointment of a named executive to a C-suite officer role. The CFO appointment is the primary event, with Higa's retirement presented as a secondary transition matter. This is material as CFO changes affect investor assessment of financial leadership and strategy execution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T13:01:55.620129+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11977,"accession_number":"0001193125-26-286957","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Eric Hyllengren as Chief Financial Officer effective July 13, 2026, with responsibility for Principal Financial Officer and Principal Accounting Officer roles. While the disclosure includes compensatory arrangements (base salary of $490,000, 40% target bonus, and 1,650,000 option grant), the principal disclosed action is the appointment of a named executive to a C-suite officer position. The filing also notes the transition of interim duties from Faraz Ali and Tomohiro Higa, but the core event is Hyllengren's appointment as CFO.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T13:01:55.620129+00:00","company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","filing_date":"2026-06-29"},{"id":11978,"accession_number":"0001193125-26-286957","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing announces the appointment of Eric Hyllengren as Chief Financial Officer, effective July 13, 2026. While the press release also mentions the retirement of Hiro Higa, the principal disclosed action centers on the appointment of a named executive to a C-suite officer role. The CFO appointment is the primary event, with Higa's retirement presented as a secondary transition matter. This is material as CFO changes affect investor assessment of financial leadership and strategy execution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T13:01:55.620129+00:00","company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","filing_date":"2026-06-29"}]}